The pharmacokinetics of etanercept in patients with heart failure [1]

British Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2001, Pages 191-192

  Soran, Ozlem ^a   Mfeldman, Arthur ^a   Schneider, Virginia M ^a   Hanna, Roberta ^b   Mann, Douglas L ^c   Korth Bradley, Joan M ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b AMGEN INC   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HEART FAILURE; HUMAN; INJECTION SITE; LETTER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0035099758     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2001.01279.x     Document Type: Letter

References (8)

1. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
2. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)
3. Etanercept. A review of its use in rheumatoid arthritis
4. The pharmacokinetics of etanercept in healthy volunteers
5. Clinical pharmacokinetics in heart failure: An updated review
6. Drug-patient interactions and their relevance in the treatment of heart failure
7. Results of a multidose phase 1 trial with Enbrel (Etanercept, p75 TNF receptor fusion protein) in patients with heart failure
8. Guidelines for collection and analysis of pharmacokinetic data